Key Highlights

  • Paysign's second-quarter 2026 Revenue rose 48.1% to $28.25 million, with its pharmaceutical patient-affordability segment growing 88.9% to $14.65 million.
  • OmniAb raised its 2026 cash guidance to $49 million to $53 million from $37 million to $41 million on August 17, 2026, the same day it disclosed a licensing deal with Eli Lilly.
  • Tectonic Therapeutic completed enrollment of 191 patients in its APEX Phase 2 trial for pulmonary hypertension on June 10, 2026, with topline results expected in early first quarter 2027.
  • Silence Therapeutics completed patient dosing in its Phase 2 SANRECO trial of divesiran for polycythemia vera in June 2026, evaluating 48 phlebotomy-dependent patients.

A closer look at five Nasdaq tickers grouped under a services banner reveals that only one, Paysign, actually belongs there, while the other four are clinical-stage or platform biotechs whose September 2026 catalysts deserve to be judged on their own terms. Tectonic Therapeutic (NASDAQ:TECX), Paysign (NASDAQ:PAYS), Silence Therapeutics (NASDAQ:SLN), OmniAb (NASDAQ:OABI) and Adlai Nortye Group (NASDAQ:ANL) are all healthcare names, and three of the four develop drugs rather than sell services.

That gap matters for how you interpret them inside the Nasdaq Composite, a broad market-cap-weighted index whose thousands of members lean heavily toward technology and healthcare. Grouping a payments processor with three oncology and cardiometabolic biotechs and one antibody-discovery platform does not describe a sector so much as a coincidence of listing venue.

What the Composite Actually Rewards Here

The Nasdaq Composite is not a services index, and none of these five is a bellwether for Business and commercial services the way a staffing giant or a Payroll processor might be. What the group does illustrate is a recurring feature of the Composite: small- and mid-cap issuers whose share prices hinge on binary or step-change events rather than on steady operating cadence.

For Paysign, that cadence is real and improving, driven by contract wins in pharmaceutical patient-affordability programs. For the biotechs, the drivers are clinical readouts, licensing deals and cash runway. These are different risk profiles wearing the same index membership.

Paysign (NASDAQ:PAYS): The Only True Services Name in the Group

Paysign, formerly 3Pea International, is a prepaid card program manager and payments-services provider, and it is the one company here that fits the business and commercial services description without qualification.

Paysign reported second-quarter 2026 results for the period ended June 30, 2026 with revenue of $28.25 million, up 48.1% year over year, according to its August 5, 2026 press release. The company split that between its plasma-donor-compensation business at $13.04 million, up 21.4%, and its faster-growing pharmaceutical patient-affordability segment at $14.65 million, up 88.9%. Net Income was $6.76 million and Diluted Earnings per Share were $0.11. Paysign reported 148 active patient-affordability programs and 561 plasma centers on its platform.

Management raised full-year 2026 guidance to revenue of $114.0 million to $117.0 million and adjusted EBITDA of $35.0 million to $38.0 million. The mix shift toward patient affordability is the story: it is higher-margin and expanding far faster than the maturing plasma business.

OmniAb (NASDAQ:OABI): A Licensing Platform, Not a Services Vendor

OmniAb is the group's closest thing to a services-adjacent model, but it is classified as a biotechnology company, and the label needs care. Rather than developing its own drugs, OmniAb licenses its antibody-discovery technology to pharmaceutical partners and earns through license fees, milestone payments and Downstream royalties.

OmniAb announced on August 17, 2026 that it raised its 2026 cash guidance to a range of $49 million to $53 million, up from $37 million to $41 million, citing recent licensing activity, and on the same day disclosed a global collaboration and license agreement with Eli Lilly for an ion-channel program. Aggregated data show the company reported roughly 107 active partners and 407 active programs at the end of 2025.

OmniAb's Economics resemble a Royalty and licensing business more than a drug developer's, which is why it can feel services-like. The value sits in partners' pipelines advancing to milestones and eventual royalties, an outcome OmniAb does not control and cannot schedule.

Tectonic Therapeutic (NASDAQ:TECX): A Cardiometabolic Biotech, Not a Services Company

Tectonic Therapeutic is a clinical-stage biotechnology company, not a business-services provider. It develops therapeutic proteins and antibodies that modulate G-protein-coupled receptors using its GEODe platform.

Tectonic announced on June 10, 2026 that it completed enrollment in its APEX Phase 2 trial of lead candidate TX45, an Fc-relaxin fusion protein activating the RXFP1 receptor, in pulmonary hypertension associated with heart failure with preserved ejection fraction. The company said the study enrolled 191 patients across 14 countries, with roughly 72% in the more severe combined pre- and post-capillary subtype, and that topline results are expected in early first quarter 2027.

TX45 is the whole thesis; there is little Diversification to cushion a disappointing readout. A positive APEX result could reprice the stock sharply, while a miss would do the same in the other direction.

Silence Therapeutics (NASDAQ:SLN): An RNAi Biotech Wearing a Services Label

Silence Therapeutics is a clinical-stage biotechnology company developing short-interfering-RNA therapies through its mRNAi GOLD platform. It is not a business or commercial services company, and its inclusion in this basket is a misclassification worth stating plainly.

Silence reported second-quarter 2026 results on August 10, 2026. Its lead program, divesiran, a first-in-class siRNA targeting TMPRSS6 for polycythemia vera, completed patient dosing in its Phase 2 SANRECO trial in June 2026, evaluating 48 phlebotomy-dependent patients. The company also progresses SLN312, an ANGPTL3 silencer partnered with AstraZeneca, in Phase 1. Silence reported cash and equivalents of $72.1 million at June 30, 2026 and a second-quarter net loss of $12.3 million, narrower than the $27.4 million loss a year earlier.

The AstraZeneca Partnership provides validation and some non-dilutive support that pure-play peers lack. Divesiran data and the pace of pipeline advancement toward planned 2027 IND filings will drive sentiment.

Adlai Nortye Group (NASDAQ:ANL): A Newly Renamed Oncology Biopharma

Adlai Nortye is a clinical-stage oncology biopharmaceutical company whose American Depositary Shares trade on Nasdaq. It is a drug developer, not a services business, and it recently underwent a corporate identity change investors should note.

The company redomiciled from the Cayman Islands to Singapore, completed July 29, 2026, and adopted the name Adlai Nortye Group Ltd. Its ADSs began trading under the new name on August 21, 2026 while retaining the existing ANL ticker and CUSIP. The pipeline centers on oncology Assets including buparlisib, which has been studied in the Phase III BURAN trial in recurrent or metastatic head and neck squamous cell carcinoma.

A redomicile and rename are administrative rather than clinical events; they change the corporate wrapper, not the science. As a foreign private issuer with a concentrated oncology pipeline, Adlai Nortye carries the usual clinical, regulatory and financing risks.

What Investors Should Watch

Watch Paysign's program-win momentum in patient affordability, because that segment, not plasma, is now carrying growth, and any client concentration or contract loss would show up quickly against the raised full-year guidance. Watch OmniAb's milestone and royalty flow, and how much of the higher 2026 cash guidance reflects durable partner activity versus one-off licensing payments. For the three drug developers, watch the calendar: Tectonic's APEX topline in early first quarter 2027 is the nearest binary event, alongside Silence's divesiran progression and Adlai Nortye's pipeline and funding after its Singapore redomicile.

Unbundle the Basket

The headline theme does not hold. Only Paysign is a genuine business and commercial services company, and it happens to be the most straightforward of the five: a growing, profitable payments processor with raised 2026 guidance and a favorable mix shift, tempered by client-concentration risk. The other four are healthcare names that belong to different conversations. The honest takeaway for September 2026 is to judge Paysign as a services operator and judge the biotechs as biotechs.